Biosimilars in rheumatology: Current perspectives and lessons learnt

Nature Reviews Rheumatology

Volumn 11, Issue 12, 2015, Pages 713-724

  Dörner, Thomas ^a   Kay, Jonathan ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABP 501; ADALIMUMAB; AVENT; BCD 057; BI 695501; BIOSIMILAR AGENT; BOW 050; BX 2922; CHS 0214; CHS 1420; CT P 13; DWP 422; ENIA 11; ETANERCEPT; GP 2015 C; GP 2017; HD 203; INFLIXIMAB; LBAL; LBEC 0101; ONS 3010; PF 06410293; PF 06438179; PRX 106; RITUXIMAB; SB 2; SB 4; SB 5; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZRC 3197; ANTIRHEUMATIC AGENT;

DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG POTENCY; DRUG PURITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; IMMUNOGENICITY; INCIDENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; RHEUMATIC DISEASES;

ANTIRHEUMATIC AGENTS; BIOSIMILAR PHARMACEUTICALS; DRUG MONITORING; HUMANS; INFLIXIMAB; RHEUMATIC DISEASES;

EID: 84948714780     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.110     Document Type: Review

References (70)

1. Dörner, T., et al. The role of biosimilars in the treatment of rheumatic diseases. Ann. Rheum. Dis. 72, 322-328 (2013
2. Scheinberg, M. A.,&Kay, J. The advent of biosimilar therapies in rheumatology-O Brave New World. Nat. Rev. Rheum. 8, 430-436 (2012
3. Schneider, C. K. Biosimilars in rheumatology: the wind of change. Ann. Rheum. Dis. 72, 315-318 (2013
4. Aringer, M.,&Dörner, T. Biosimilars. Current state of the build up to series production [German]. Z. Rheumatol. 72, 873-877 (2013
5. Castañeda-Hernandez, G., et al. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Joint Bone Spine 81, 471-477 (2014
6. European Medicines Agency. Guideline on similar biological medicinal products [online], www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf (2014
7. Barile-Fabris, L A., Irazoque-Palazuelos, F., Vasquez, R. H., Vazquez, S. C.,&Guzman, R. Incidence of adverse events in patients treated with intended copies of biologic therapeutic agents in Colombia and Mexico [abstract 1506]. Arthritis Rheumatol. 66, S662 (2014
8. Enbrel® (etanercept) product monograph (Immunex Corporation&Amgen Canada Inc., 2013) [online], https://www.amgen.ca/Enbrel-PM.pdf (2013
9. Castañeda-Hernández, G., Gonzalez-Ramirez, R., Kay, J.,&Scheinberg, M. Biosimilars in rheumatology: what clinicians should know. RMD Open 2015, e000010 (2015
10. Yi, S., et al. Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers. BioDrugs 26, 177-184 (2012
11. Bae, S C., et al A randomized, double-blind, phase 3 equivalence trial comparing the etanercept biosimilar, HD203, with etanercept (Enbrel®), in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) [abstract]. Arthritis Rheumatol. 66, S1234 (2014
12. MDMagazine.com. HD203 biosimilar is clinically equivalent to etanercept [online], http://www.hcplive.com/conferences/acr 2014/HD203 Biosimilar is Clinically Equivalent to Etanercept (2014
13. European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use (EMA/9499/2015). European Medicines Agency [online], http://www.ema.europa.eu/docs/en-GB/document-library/Report/2015/01/WC500180332.pdf (2015
14. Park, W., et al A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis. 72, 1605-1612 (2013
15. Yoo, D. H., et al A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann. Rheum. Dis. 72, 1613-1620 (2013
16. Celltrion. Celltrions Remsima™ (infliximab) receives positive opinion from EMAs CHMP. Celltrion [online], http://www.celltrion.com/en/company/notice-view.asp?idx=364&code=ennews&intNowPage=3&menu-num=&align-year=all (2013
17. Egis Pharmaceuticals PLC. Egis is first to launch biosimilar monoclonal antibody within the European Union. Budapest Stock Exchange Ltd [online], http://bse.hu/newkibdata/115250544/EGI130913ER01E.pdf (2013
18. Serebrov, M. Celltrion hopes to blaze path for first U. S. biosimilar MAb. BioWorld™ [online], http://www.bioworld.com/content/celltrion-hopes-blaze-path-first-us-biosimilar-mab-0 (2014
19. Song-hoon, L. Celltrion gets license to sell Remsima in Venezuela. BusinessKorea [online], http://www.businesskorea.co.kr/article/10350/winning-bids-celltrion-gets-license-sell-remsima-venezuela (2015
20. No authors listed]. Biosimilar infliximab receives approval in Japan and Turkey. Generics and Biosimilars Initiative [online], http://www.gabionline.net/Biosimilars/News/Biosimilar-infliximab-receives-Approval-in-Japan-And-Turkey (2014
21. Health Canada. Inflectra. Drugs and Health Products [online], http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2014-inflectra-159493-eng.php (2015
22. Hazlewood, G. S., et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohns disease: a network meta-Analysis. Gastroenterology 148, 344-354 (2015
23. Kawalec, P., Mikrut, A., Wisniewska, N.,&Pilc, A. Tumor necrosis factor á antibodies (infliximab, adalimumab and certolizumab) in Crohns disease: systematic review and meta-Analysis. Arch. Med. Sci. 9, 765-779 (2013
24. No authors listed]. Biosimilar infliximab approved in Japan, but not with full extrapolation. The Biosimilarz Blog! [online], http://www.biosimilarz.com/?p=535 (2014
25. Lambert, J., et al. Pharmacokinetic results from a phase 1, single-centre, double-blind, randomised, single-dose, parallel group study comparing 5 mg/kg IV infusion of BOW015 and reference infliximab in healthy male volunteers [abstract]. Ann. Rheum. Dis. 74 (Suppl. 2), 462 (2015
26. Kay, J., et al BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses: 54-week results of a randomized, double-blind, active comparator study [abstract L20]. Arthritis Rheumatol. 66, 3538 (2014
27. No authors listed]. Infliximab similar biologic receives Indian approval. Generics and Biosimilars Initiative [online], http://www.gabionline.net/Biosimilars/News/Infliximab-similar-biologic-receives-Indian-Approval (2014
28. Zydus Cadila. Zydus launches worlds first biosimilar of Adalimumab. Zydus Cadila [online], http://zyduscadila.com/wp-content/uploads/2015/05/PressNote09-12-14.pdf (2014
29. Bandyopadhyay, S., et al Physicochemical and functional characterization of a biosimilar adalimumab ZRC 3197. Biosimilars 5, 1-18 (2015
30. Exemptia. Clinical Data [online], http://exemptia.com/HealthCareProfessionals/exemptia-clinical-data (2015
31. Exemptia. Adalimumab. Exemptia [online], http://exemptia.com/wp-content/uploads/2014/11/2042124-Open-PI-Exemptia-PFS-Injection-40mg-8ml-Sale.pdf (2014
32. Braun, J., Baraliakos, X., Kudrin, A., Kim, H.,&Lee, S J. Striking discrepancy in the development of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in response to infliximab (INF) and its biosimilar CT P13 [abstract L21]. Arthritis Rheumatol. 66, 3538-3539 (2014
33. Udata, C., et al. Immunogenicity assessment of PF 06438179, a potential biosimilar to infliximab, in healthy volunteers [abstract SAT0142]. Ann. Rheum. Dis. 74 (Suppl. 2), 702 (2015
34. Kay, J., Lassen, C., Trokan, L.,&Wyand, M. Safety profile of BOW015, a biosimilar infliximab, in healthy subjects and patients with active rheumatoid arthritis [abstract]. Ann. Rheum. Dis. 74 (Suppl. 2), 706 (2015
35. Mok, C. C., van der Kleij, D.,&Wolbink, G. J. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF α biologics in rheumatic diseases. Clin. Rheumatol. 32, 1429-1435 (2013
36. van Schouwenburg, P. A., Rispens, T.,&Wolbink, G. J. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 9, 164-172 (2013
37. Mazilu, D., et al. Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment. Biomed. Res. Int. 2014, 702701. (2014
38. DHaens, G. R., Sartor, R. B., Silverberg, M. S., Petersson, J.,&Rutgeerts, P. Future directions in inflammatory bowel disease management. J. Crohns Colitis 8, 726-734 (2014
39. US Department of Health&Human Services. The Affordable Care Act. HHS.gov/HealthCare [online], http://www.hhs.gov/healthcare/rights/law/index.html (2015
40. ACR Committee on Rheumatologic Care. ACR Position Statements-Biosimilars. American College of Rheumatology [online], http://www.rheumatology.org/Practice/Clinical/Position/Biosimilars-02-2015/.pdf (2015
41. EULAR. Biosimilars: what do patients need to consider?. The European League Against Rheumatism [online], http://www.eular.org/myUploadData/files/Biosimilars-2015.pdf (2015
42. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02148640 (2015
43. Curtis, J. R., et al A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis registries. Semin. Arthritis Rheum. 40, 2-14 (2010
44. No authors listed] The INN crowd. Nat. Biotechnol. 31, 1055 (2013
45. World Health Organization. 55th Consultation on International Nonproprietary Names for Pharmaceutical Substances, Geneva, 16-18 October 2012 [online], www.who.int/medicines/services/inn/55th-Executive-Summary.pdf (2013
46. European Commission. Commission implementing directive 2012/52/EU of 20 December 2012 laying down measures to facilitate the recognition of medical prescriptions issued in another Member State [online], http://ec.europa.eu/health/cross-border-care/docs/impl-directive-presciptions-2012-en.pdf (2012
47. Pineda, C., et al. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. Clin. Rheumatol. 34, 635-640 (2015
48. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: nonclinical and clinical issues. European Medicines Agency [online], http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/01/WC500180219.pdf (2006
49. US Department of Health&Human Services. Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009.US Food and Drug Administration [online], http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm444661.pdf (2012
50. Arguelles-Arias, F., Barreiro-de Acosta, M., Carballo, F., Hinojosa, J.,&Tejerina, T. Joint position statement by Sociedad Espanola de Patologia Digestiva (Spanish Society of Gastroenterology) and Sociedad Espanola de Farmacologia (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease. Rev. Esp. Enferm. Dig. 105, 37-43 (2013
51. Danese, S.,&Gomollon, F. ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J. Crohns Colitis 7, 586-589 (2013
52. Danese, S., Florino, G.,&Michetti, P. Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohns and Colitis Organization. J. Crohns Colitis 8, 1548-1550 (2014
53. Fiorino, G.,&Danese, S. The biosimilar road in inflammatory bowel disease: the right way?. Best Pract. Res. Clin. Gastroenterol. 28, 465-471 (2014
54. Fiorino, G., et al. The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun. Rev. 13, 751-755 (2014
55. Gecse, K. B., et al. Biosimilars in IBD: hope or expectation?. Gut 62, 803-807 (2013
56. Hlavaty, T.,&Letkovsky, J. Biosimilars in the therapy of inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 26, 581-587 (2014
57. Schreiber, S., et al. Evolution of biologicals in inflammation medicine-biosimilars in gastroenterology, rheumatology and dermatology [German]. Dtsch Med. Wochenschr. 139, 2399-2404 (2014
58. US National Library of Medicine. Clinicaltrials.gov [online], http://www.clinicaltrials.gov (2015
59. European Medicines Agency. EU Clinical Trials Register [online], https://www.clinicaltrialsregister.eu (2015
60. No authors listed]. Biosimilars of adalimumab. Generics and Biosimilars Initiative [online], http://www.gabionline.net/Biosimilars/General/Biosimilars-of-Adalimumab (2014
61. No authors listed]. Biosimilars of etanercept. Generics and Biosimilars Initiative [online], http://gabionline.net/Biosimilars/General/Biosimilars-of-etanercept (2014
62. Protalix Biotherapeutics. PRX-106 (Oral antiTNF). Protalix Biotherapeutics [online], http://www.protalix.com/development-pipeline/prx-106-Autoimmune.asp (2015
63. Emery, P., et al A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2015-207588
64. No authors listed]. Biosimilars of infliximab. Generics and Biosimilars Initiative [online], http://www.gabionline.net/Biosimilars/General/Biosimilars-of-infliximab (2015
65. Amgen Biosimilars. Our pipeline. Amgen Biosimilars [online], http://www.amgenbiosimilars.com/our-products/our-pipeline/(2015
66. Epirus Biopharmaceuticals. BOW070 (tocilizumab). Epirus Biopharmaceuticals [online], http://www.epirusbiopharma.com/programs/bow070-Tocilizumab.php (2015
67. No authors listed]. Biosimilars of rituximab. Generics and Biosimilars Initiative [online], http://www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab (2015
68. LatinLink. Latin America pharma. LatinLink [online], http://www.latinlink.com/tag/latin-America-pharma/(2015
69. Azevedo, V. F., Galli, N., Kleinfelder, A., DIppolito, J.,&Urbano, P. C. Etanercept biosimilars. Rheumatol. Int. 35, 197-209 (2015
70. Vital, E. M, Kay, J.,&Emery, P. Rituximab biosimilars. Expert Opin. Biol. Ther. 13, 1049-1062 (2013